门诊伏立康唑治疗药物监测算法的开发:多中心回顾性研究
本研究在多中心回顾性分析2017至2021年141例门诊伏立康唑患者(578次浓度监测)的谷浓度与临床事件关联。治疗组和预防组异常浓度比例分别为29.0%和31.5%,低浓度治疗组临床症状加重最常见(18.2%),高浓度组不良反应最常见。研究基于临床事件开发了门诊TDM实施算法,但需未来干预验证。
要点
- 门诊伏立康唑治疗与预防组中约三成患者谷浓度异常。
- 低浓度治疗组临床症状加重比例最高(18.2%)。
- 高浓度组肝毒性和视觉障碍发生率更高,预防组肝毒性达27.9%。
核心结论
- 基于临床事件开发了门诊伏立康唑TDM实施算法,但需未来干预验证。
研究设计与样本
- 多中心回顾性研究,纳入2017至2021年三家机构接受伏立康唑的门诊患者141例(578次浓度测量)。
主要发现
- 治疗组37例(131次测量)和预防组104例(447次测量)中异常浓度患者比例分别为29.0%和31.5%。
- 两组中异常浓度均占首次测量浓度的50%。
- 低浓度治疗组临床症状加重最常见(18.2%)。
- 高浓度组不良反应最常见:治疗组肝毒性6.3%、视觉障碍18.8%;预防组肝毒性27.9%。
- 合并用药变化和药物相互作用无差异;预防组有临床事件者处方持续时间 tended 更长(47.4±23.4天 vs 39.7±21.9天,P=.1132)。
关键数值与推荐
- 异常谷浓度定义为<1.0 mg/L(低浓度组)和>4.0 mg/L(高浓度组)。
临床怎么用
- 门诊伏立康唑TDM可依据临床事件算法选择性实施,而非全部患者。
局限性
- 算法需未来干预研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Although therapeutic drug monitoring (TDM) of voriconazole is performed in outpatients to prevent treatment failure and toxicity, whether TDM should be performed in all or only selected patients remains controversial. This study evaluated the association between voriconazole trough concentrations and clinical events. METHODS: We investigated the aggravation of clinical symptoms, incidence of hepatotoxicity and visual disturbances, change in co-medications and interaction between voriconazole and co-medications in outpatients receiving voriconazole between 2017 and 2021 in three facilities. Abnormal trough concentrations were defined as <1.0 mg/L (low group) and >4.0 mg/L (high group). RESULTS: A total of 141 outpatients (578 concentration measurements) met the inclusion criteria (treatment, 37 patients, 131 values; prophylaxis, 104 patients, 447 values). The percentages of patients with abnormal concentrations were 29.0% and 31.5% in the treatment and prophylaxis groups, respectively. Abnormal concentrations showed 50% of the concentrations at the first measurement in both therapies. Aggravation of clinical symptoms was most frequently observed in the low treatment group (18.2%). Adverse events were most common in the high group for both therapies (treatment, hepatotoxicity 6.3%, visual disturbance 18.8%; prophylaxis, hepatotoxicity 27.9%). No differences were found in changes to co-medications and drug interactions. In the prophylaxis group, prescription duration in the presence of clinical events tended to be longer than in their absence (47.4 ± 23.4 days vs 39.7 ± 21.9 days, P = .1132). CONCLUSIONS: We developed an algorithm based on clinical events for appropriate implementation of TDM in outpatients. However, future interventions based on this algorithm should be validated.
引用
- Kato H, Umemura T, Hagihara M, et al. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study. Br J Clin Pharmacol. 2024. PMID: 38320604. doi:10.1111/bcp.16004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。